MannKind slides after halting late-stage trial of MNKD-101 for lung disease

Core Viewpoint - MannKind Corporation (MNKD) experienced a significant stock decline following the announcement to discontinue its trial testing of MNKD-101, a nebulized form of clofazimine aimed at treating refractory nontuberculous mycobacterial lung disease [2]. Company Summary - The stock of MannKind Corporation fell by 10% in premarket trading after the announcement regarding the discontinuation of MNKD-101 trials [2].